Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Cancer vaccine targets immortalisation factor in cancer cell

04.07.2002


A new vaccination strategy targeting telomerase, one of the enzymes responsible for making cancer cells immortal, has been developed at the Norwegian Radium Hospital. "The vaccine might offer a means of stabilising cancer", states Professor Gustav Gaudernack at a press conference at the 18th UICC International Cancer Congress in Oslo this week.



A new vaccination strategy targeting telomerase, one of the enzymes responsible for making cancer cells immortal, has been tested by Professor Trond Buanes on patients with pancreatic cancer at Ullevaal University Hospital. The vaccine was developed by a research team headed by Professor Gustav Gaudernack at the Norwegian Radium Hospital.

Initiated in September 2000, the ongoing study comprises 31 patients with inoperable pancreatic cancer who have been treated with the vaccine. With the optimal dose, the majority of the patients have experienced an immune response to the vaccine. There is a trend for these patients to live longer than those who failed to respond, and for the patients who received a higher dose to live longer than those who received the lower dose. Gaudernack warns that since there was little evidence of tumour reduction, this is not a cure but rather a means of stabilising the cancer.


The vaccine has been designed to encourage the immune system to respond to telomerase produced by cancer cells. Found in virtually all types of cancer, this target is responsible for giving cancer cells an unlimited capacity to divide. The immunologists’ aim is to stimulate the patient’s own immune system to recognise this protein and destroy the cancer cells while leaving the healthy cells alone. There are still some questions related to the long-term safety of the vaccine.

Gaudernack emphasises the need to verify these results by controlled studies on larger groups of patients.

These research efforts are supported by the Norwegian Cancer Society and the Norwegian biotech company GemVax.


Contacts:
Researcher Gustav Gaudernack, Norwegian Radium Hospital
Tel +47 22 93 40 00

18th UICC International Cancer Congress,
Press Office: Hanna Hånes
Tel +47 901 56 040, e-mail: haanes@oslo2002.org

Hanna Hånes | EurekAlert!
Further information:
http://www.kreft.no/

More articles from Health and Medicine:

nachricht UC San Diego cancer scientists identify new drug target for multiple tumor types
12.07.2019 | University of California - San Diego

nachricht Bacteria engineered as Trojan horse for cancer immunotherapy
04.07.2019 | Columbia University School of Engineering and Applied Science

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Megakaryocytes act as „bouncers“ restraining cell migration in the bone marrow

Scientists at the University Würzburg and University Hospital of Würzburg found that megakaryocytes act as “bouncers” and thus modulate bone marrow niche properties and cell migration dynamics. The study was published in July in the Journal “Haematologica”.

Hematopoiesis is the process of forming blood cells, which occurs predominantly in the bone marrow. The bone marrow produces all types of blood cells: red...

Im Focus: Artificial neural network resolves puzzles from condensed matter physics: Which is the perfect quantum theory?

For some phenomena in quantum many-body physics several competing theories exist. But which of them describes a quantum phenomenon best? A team of researchers from the Technical University of Munich (TUM) and Harvard University in the United States has now successfully deployed artificial neural networks for image analysis of quantum systems.

Is that a dog or a cat? Such a classification is a prime example of machine learning: artificial neural networks can be trained to analyze images by looking...

Im Focus: Extremely hard yet metallically conductive: Bayreuth researchers develop novel material with high-tech prospects

An international research group led by scientists from the University of Bayreuth has produced a previously unknown material: Rhenium nitride pernitride. Thanks to combining properties that were previously considered incompatible, it looks set to become highly attractive for technological applications. Indeed, it is a super-hard metallic conductor that can withstand extremely high pressures like a diamond. A process now developed in Bayreuth opens up the possibility of producing rhenium nitride pernitride and other technologically interesting materials in sufficiently large quantity for their properties characterisation. The new findings are presented in "Nature Communications".

The possibility of finding a compound that was metallically conductive, super-hard, and ultra-incompressible was long considered unlikely in science. It was...

Im Focus: Modelling leads to the optimum size for platinum fuel cell catalysts: Activity of fuel cell catalysts doubled

An interdisciplinary research team at the Technical University of Munich (TUM) has built platinum nanoparticles for catalysis in fuel cells: The new size-optimized catalysts are twice as good as the best process commercially available today.

Fuel cells may well replace batteries as the power source for electric cars. They consume hydrogen, a gas which could be produced for example using surplus...

Im Focus: The secret of mushroom colors

Mushrooms: Darker fruiting bodies in cold climates

The fly agaric with its red hat is perhaps the most evocative of the diverse and variously colored mushroom species. Hitherto, the purpose of these colors was...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on UV LED Technologies & Applications – ICULTA 2020 | Call for Abstracts

24.06.2019 | Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

 
Latest News

For bacteria, the neighbors co-determine which cell dies first: The physiology of survival

17.07.2019 | Life Sciences

Harvesting energy from the human knee

17.07.2019 | Physics and Astronomy

Neutrino-Observatorium IceCube am Südpol wird ausgebaut

17.07.2019 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>